Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
US5908923A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 29, 1997 |
| Grant date | Jun 1, 1999 |
| Priority date | — |
| Expiry date | Apr 29, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16222
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of using a transdominant negative integrase gene to make at least one cell resistant to a retroviral infection which includes retroviral infections resulting from HIV; a method for introducing a transdominant negative integrase gene into at least one mammalian cell to make said cell resistant to a retroviral infection as well as vectors, cells, and methods of constructing same useful in the aforementioned methods; a method of treating AIDS comprising administering to a patient an effective amount of a transdominant negative integrase gene alone or combined with agents useful for gene therapy inhibition of HIV, antiviral agents, or interleukin-2; and pharmaceutical delivery methods which include a transdominant negative integrase gene alone or combined with agents useful for gene therapy inhibition of HIV, antiviral agents, or interleukin-2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.